# Matthew R. Sydes

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/matthew-r-sydes/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,517 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 79 |
| i10-index | 223 |
| Last Known Institution | MRC Clinical Trials Unit at UCL |
| OpenAlex ID | https://openalex.org/A5059261043 |
| ORCID iD | https://orcid.org/0000-0002-9323-1371 |
| Works | 495 |

## Researcher papers

- [Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial](https://scholariq.org/papers/addition-of-docetaxel-zoledronic-acid-or-both-to-first-line-long-term-hormone/)
- [Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy](https://scholariq.org/papers/abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy/)
- [Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial](https://scholariq.org/papers/radiotherapy-to-the-primary-tumour-for-newly-diagnosed-metastatic-prostate/)
- [Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort](https://scholariq.org/papers/survival-and-prognosis-with-osteosarcoma-outcomes-in-more-than-2000-patients-in/)
- [The Lancet Commission on prostate cancer: planning for the surge in cases](https://scholariq.org/papers/the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial](https://scholariq.org/papers/comparison-of-mapie-versus-map-in-patients-with-a-poor-response-to-preoperative/)
- [Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial](https://scholariq.org/papers/methotrexate-doxorubicin-and-cisplatin-map-plus-maintenance-pegylated-interferon/)
- [Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial](https://scholariq.org/papers/timing-of-radiotherapy-after-radical-prostatectomy-radicals-rt-a-randomised/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment](https://scholariq.org/papers/euramos-1-an-international-randomised-study-for-osteosarcoma-results-from-pre/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Statistical Methods in Clinical Trials](https://scholariq.org/topics/statistical-methods-in-clinical-trials/)
- [Ethics in Clinical Research](https://scholariq.org/topics/ethics-in-clinical-research/)
- [Meta-analysis and systematic reviews](https://scholariq.org/topics/meta-analysis-and-systematic-reviews/)

## Researcher university

- [MRC Clinical Trials Unit at UCL](https://scholariq.org/institutions/mrc-clinical-trials-unit-at-ucl/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.